Resolution Therapeutics is a clinical stage pioneer in Regenerative Macrophage Therapies (RMT) for Inflammatory and Fibrotic Diseases. CLINICAL PROGRAM / HIGH UNMET NEED - EMERALD/OPAL (P1/2) for End Stage Liver Disease (ESLD), which affects >500k people in the US with liver transplantation as the only option, leaving over 90% of patients with no alternative. TRANSFORMATIVE TREATMENT - Engineered macrophages with enhanced anti-inflammatory and anti-fibrotic efficacy, optimised by payload ROBUST SCIENCE & CLINICAL EVIDENCE - Two clinical Proof of Concept studies demonstrating safety and efficacy in patients with cirrhosis; robust biomarker package FOCUSED PIPELINE - Efficacy demonstrated in lung fibrosis and GvHD with platform expansion into In Vivo modality